Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats

Journal of Pharmacokinetics and Biopharmaceutics
W Schmidt, E Jähnchen


The interaction of phenylbutazone with the enantiomers and racemic [3H]phenprocoumon was studied in male inbred Wistar-Lewis rats following a single i.v. dose of the three forms of phenprocoumon and chronic oral treatment with phenylbutazone (average plasma concentration of about 60 microgram/ml). Phenylbutazone augmented the anticoagulant effect of R(+), S(-), and R, S(+/-) phenprocoumon to a similar extent. The free fraction of drug in the plasma of the enantiomers and racemic phenprocoumon increased in the presence of phenylbutazone. However, the rate of elimination of total drug from plasma and liver and the distribution between liver and plasma of all three forms of phenprocoumon remained nearly unaffected by phenylbutazone. Thus there is no evidence for a stereoselective drug interaction between phenprocoumon and phenylbutazone. For racemic [oH]phenprocoumon it was possible to follow the kinetics of free drug in plasma and liver along with the time course of anticoagulant activity. In these studies, free drug concentrations in plasma and liver increased during treatment with phenylbutazone, but the elimination rate constant of free racemic phenprocoumon in plasma and liver remained essentially unchanged. Phenylbutazone ma...Continue Reading


Nov 1, 1975·The Journal of Pharmacy and Pharmacology·K Bachmann, A M Burkman
May 1, 1977·The Journal of Pharmacy and Pharmacology·W Schmidt, E Jähnchen
Jul 1, 1978·Clinical Pharmacology and Therapeutics·M GibaldiP J McNamara
Jan 1, 1976·Annals of the New York Academy of Sciences·G Levy
Aug 1, 1977·Journal of Pharmaceutical Sciences·J J Thiessen, M Rowland
Aug 1, 1977·Journal of Pharmaceutical Sciences·M Gibaldi, P J McNamara
Sep 1, 1976·Clinical Pharmacology and Therapeutics·E JähnchenA Martini
May 1, 1975·Journal of Medicinal Chemistry·L R PohlW F Trager
Oct 1, 1975·Clinical Pharmacology and Therapeutics·G R Wilkinson, D G Shand
Nov 1, 1969·Clinical Pharmacology and Therapeutics·R D WelchJ J Burns
Jul 6, 1971·Annals of the New York Academy of Sciences·J R Gillette
Nov 15, 1973·Klinische Wochenschrift·R Gugler, H J Dengler
May 1, 1974·Journal of Pharmaceutical Sciences·G Levy, A Yacobi
Jun 1, 1974·The Journal of Clinical Investigation·R J LewisW Schary
Jan 1, 1969·Clinical Pharmacology and Therapeutics·R NagashimaG Levy
Mar 2, 1967·The New England Journal of Medicine·P M AggelerP E Kowitz
Jul 7, 1967·Biochemical Pharmacology·H M Solomon, J J Schrogie
Apr 20, 1964·JAMA : the Journal of the American Medical Association·S L FOX
Jul 6, 1964·JAMA : the Journal of the American Medical Association·M J EISEN


Jan 1, 1989·European Journal of Clinical Pharmacology·D TrenkE Jähnchen
Jan 1, 1981·Pharmacology & Therapeutics·L Aarons
Apr 1, 1981·British Journal of Clinical Pharmacology·E JähnchenD Trenk
Jun 1, 1988·The Journal of Pharmacy and Pharmacology·D TrenkS Oie
Feb 1, 1988·Journal of Pharmacokinetics and Biopharmaceutics·D TrenkS Oie
Apr 1, 1980·Journal of Pharmacokinetics and Biopharmaceutics·D Trenk, E Jähnchen
Dec 1, 1980·The Journal of Pharmacy and Pharmacology·D TrenkE Jähnchen

Related Concepts

Indirect Thrombin Inhibitors
Drug Interactions
Molecular Stereochemistry
Rats, Laboratory

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Laryngeal Neoplasms

Laryngeal Neoplasms occur in the Larynx and are typically associated with smoking and alcohol consumption. Discover the latest research on Laryngeal Neoplasms here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.